<DOC>
	<DOCNO>NCT02105870</DOCNO>
	<brief_summary>Microvascular dysfunction key determinant pathogenesis outcome patient suffer acute myocardial infarction . The investigator hypothesise treatment intracoronary abciximab , potent anti platelet agent , time coronary stent insertion , improve microvascular function .</brief_summary>
	<brief_title>A Randomized Trial Intracoronary Reopro Improve Coronary Microvascular Function</brief_title>
	<detailed_description>The index microcirculatory resistance ( IMR ) , invasive measure coronary microvascular function , correlate clinical outcome patient stable angina ST elevation myocardial infarction . The glycoprotein IIb/IIIa receptor inhibitor , abciximab , improve coronary microvascular function reduces major cardiac adverse event patient acute coronary syndrome . This study investigate whether intracoronary bolus abciximab patient non-ST elevation myocardial infarction decrease IMR improve microvascular function .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<criteria>Patient acute coronary syndrome Patient untreated malignancy , disseminated malignancy , active inflammatory disease , active infectious disease patient unable give inform consent Patients STEMI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>